These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15026493)

  • 21. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
    Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
    Cooper JM; Daniel SE; Marsden CD; Schapira AH
    Mov Disord; 1995 May; 10(3):295-7. PubMed ID: 7651446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
    Lang AE
    Mov Disord; 1995 Jul; 10(4):489-95. PubMed ID: 7565831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.
    Rajput AH; Rajput ML; Robinson CA; Rajput A
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
    Issy AC; Padovan-Neto FE; Lazzarini M; Bortolanza M; Del-Bel E
    Life Sci; 2015 Mar; 125():71-8. PubMed ID: 25681528
    [No Abstract]   [Full Text] [Related]  

  • 27. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
    Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
    [No Abstract]   [Full Text] [Related]  

  • 28. Atorvastatin protects GABAergic and dopaminergic neurons in the nigrostriatal system in an experimental rat model of transient focal cerebral ischemia.
    Sabogal AM; Arango CA; Cardona GP; Céspedes ÁE
    Biomedica; 2014; 34(2):207-17. PubMed ID: 24967926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
    Chen Q; Andersen AH; Zhang Z; Ovadia A; Cass WA; Gash DM; Avison MJ
    Exp Neurol; 1999 Jul; 158(1):63-75. PubMed ID: 10448418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical heterogeneity of dopa-responsive dystonia: PET observations.
    Takahashi H; Snow BJ; Nygaard TG; Calne DB
    Adv Neurol; 1993; 60():586-90. PubMed ID: 8420195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case at Salpêtrière hospital November 1990. Parkinson syndrome with poor response to dopa therapy in a 64 year-old man].
    Dubas F; Vidailhet M; Henin D
    Rev Neurol (Paris); 1992; 148(8-9):580-5. PubMed ID: 1494735
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 34. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 35. The clinical features of Parkinson's disease in 100 histologically proven cases.
    Hughes AJ; Daniel SE; Lees AJ
    Adv Neurol; 1993; 60():595-9. PubMed ID: 8420197
    [No Abstract]   [Full Text] [Related]  

  • 36. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple system atrophy: a review of 203 pathologically proven cases.
    Wenning GK; Tison F; Ben Shlomo Y; Daniel SE; Quinn NP
    Mov Disord; 1997 Mar; 12(2):133-47. PubMed ID: 9087971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future strategies for the treatment of Parkinson's disease.
    Fahn S
    Adv Neurol; 1993; 60():636-40. PubMed ID: 8420202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.